On Friday, Halozyme Therapeutics Inc (NASDAQ: HALO) was 6.27% up from the session before settling in for the closing price of $48.95. A 52-week range for HALO has been $42.01 – $70.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 39.83% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 26.57%. With a float of $121.86 million, this company’s outstanding shares have now reached $123.17 million.
In an organization with 350 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 81.81%, operating margin of 55.1%, and the pretax margin is 55.79%.
Halozyme Therapeutics Inc (HALO) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Halozyme Therapeutics Inc stocks. The insider ownership of Halozyme Therapeutics Inc is 1.10%, while institutional ownership is 100.34%. The most recent insider transaction that took place on Apr 28 ’25, was worth 271,467. In this transaction Director of this company sold 4,497 shares at a rate of $60.37, taking the stock ownership to the 28,611 shares. Before that another transaction happened on Apr 01 ’25, when Company’s Director sold 503 for $64.05, making the entire transaction worth $32,217. This insider now owns 33,108 shares in total.
Halozyme Therapeutics Inc (HALO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.57% per share during the next fiscal year.
Halozyme Therapeutics Inc (NASDAQ: HALO) Trading Performance Indicators
You can see what Halozyme Therapeutics Inc (HALO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.30. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.91. Likewise, its price to free cash flow for the trailing twelve months is 12.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.77, a number that is poised to hit 1.21 in the next quarter and is forecasted to reach 7.16 in one year’s time.
Technical Analysis of Halozyme Therapeutics Inc (HALO)
Let’s dig in a bit further. During the last 5-days, its volume was 6.29 million. That was better than the volume of 1.84 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 9.24%. Additionally, its Average True Range was 3.87.
During the past 100 days, Halozyme Therapeutics Inc’s (HALO) raw stochastic average was set at 23.76%, which indicates a significant increase from 19.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 144.03% in the past 14 days, which was higher than the 60.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $60.83, while its 200-day Moving Average is $56.38. However, in the short run, Halozyme Therapeutics Inc’s stock first resistance to watch stands at $53.63. Second resistance stands at $55.25. The third major resistance level sits at $57.74. If the price goes on to break the first support level at $49.52, it is likely to go to the next support level at $47.03. Assuming the price breaks the second support level, the third support level stands at $45.41.
Halozyme Therapeutics Inc (NASDAQ: HALO) Key Stats
There are 123,221K outstanding shares of the company, which has a market capitalization of 6.41 billion. As of now, sales total 1,015 M while income totals 444,090 K. Its latest quarter income was 264,860 K while its last quarter net income were 118,100 K.
